Indian Equities Conclude Week in Positive Territory Amidst USIran Diplomacy SpaceX Scrubs Starship Test Flight Reschedules for Friday Amid IPO BuildUp HS2s Cost Ballooning to 1027bn and Delays to 2039 Raise Fresh Questions Over UK Infrastructure Spending Tulsi Gabbard Resigns as US Intelligence Chief Amid Iran Strike Considerations Gold Prices Steady Near 4500 as Market Watches IranUS Peace Talks Puerto Ricos Top 2026 Travel Destinations Old San Juan and Vieques Highlighted as Tourism Drivers HHH Q1 2026 Earnings Earnings Per Share Beat Estimates by 73 Stock Declines Slightly RPRX Q1 2026 Earnings EPS Beat Drives Positive Stock Movement Nutrien NTR Q1 2026 Earnings EPS Miss Amidst Fertilizer Market Pressures ALOY Q1 2024 Earnings WiderthanExpected Loss Raises Concerns Despite Stock Uptick Energy Transfer ET Q1 2026 Earnings Mixed Results with EPS Miss but Slight Stock Uptick SU Q1 2026 Earnings Strong EPS Beat Reflects Operational Discipline Structure Therapeutics GPCR Edges Higher on Modest Gains Testing Key Resistance Levels ADTRAN Holdings ADTN Surges 523 as Stock Approaches Key Resistance Level Nuveen Municipal Credit Opportunities Fund NMCO Edges Higher Amid Steady Income Demand Vital Farms VITL Edges Higher Amid Steady Trading Key Levels in Focus Genesco GCO Edges Higher as Stock Tests Key Resistance Levels Indonesian Commodity Exporters Raise Concerns Over Proposed State Monopoly EXP Q1 2026 Earnings Powerful EPS Beat Highlights Cost Discipline Amid Subdued Demand Highview Merger Corp Holds Steady at 1012 Amid Minimal Movement GSBC Q1 2026 Earnings Strong EPS Beat Despite Slight Stock Decline CocaCola Consolidated Inc COKE Q1 2026 Earnings Solid EPS Amid Quiet Quarter OCGN Q1 2026 Earnings EPS Miss Highlights Ongoing Cash Burn as Pipeline Advances Sera Prognostics Q1 2026 Earnings EPS In Line with Estimates as Stock Rises 15 GBFH Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Stock Declines WMT Q1 2026 Earnings Modest EPS Miss Amidst Stable Operations Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances